Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens

@article{Weycker2014RiskOF,
  title={Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens},
  author={Derek Weycker and Xiao-yan Li and John S Edelsberg and Rich Barron and A. G. Kartashov and Hairong Xu and Gary H. Lyman},
  journal={Supportive Care in Cancer},
  year={2014},
  volume={22},
  pages={3275-3285}
}
Considerable evidence exists concerning the risk of febrile neutropenia (FN) associated with well-established, older chemotherapy regimens. Little is known, however, about the risks associated with many regimens that were introduced in the past decade and have become the predominant choice for certain cohorts of patients or are increasingly being used in clinical practice. A retrospective cohort design and US healthcare claims data (2006–2011) were employed. Study subjects included adult… CONTINUE READING